The Core Facility provides Liver Center investigators with biostatistical consultation, data analysis, interpretation, and assistance in writing up statistical methods and results; serum samples, peripheral blood mononuclear cells and liver specimens from patients with liver disease and limited clinical data from these patients. Investigation of liver disease transcends many disciplines from adult hepatology to pediatrics, from surgery to radiology to pathology, from basic immunology to clinical virology to epidemiology. Liver Center investigators have been studying questions related not only to liver transplantation and antiviral therapy but also to biliary disease, variceal bleeding, cost effectiveness and quality of life. The Core has been able to provide support for a broad range of investigations into hepatobiliary diseases and normal hepatic metabolism, and to serve as a regional and national resource for clinical research in viral hepatitis and transplant. Finally, the Core has been instrumental in bringing together a group of investigators focused on liver cancer, who now have applied for expanded funding in this area, through the NCI SPORE mechanism. The Core provides comprehensive assistance to investigators at all stages of study development and execution, including assistance with study design, database construction, statistical analysis, and manuscript writing. By removing the inertial barriers to entering clinical research, it plays a major role in the productivity and career development of UCSF trainees and junior faculty while also assisting more senior investigators with established research programs. The extensive collection of serum and tissue samples has been made available to, and utilized extensively by, Liver Center members and, on a limited basis, by non-Center investigators at other academic institutions. The diversity and number of specimens available through the Core provides a scarce and unique human resource for those engaged in clinical and translational research.

Project Start
2002-09-30
Project End
2007-05-31
Budget Start
Budget End
Support Year
21
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Type
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Schwartz, Janice B; Gallagher, J Christopher; Jorde, Rolf et al. (2018) Determination of Free 25(OH)D Concentrations and Their Relationships to Total 25(OH)D in Multiple Clinical Populations. J Clin Endocrinol Metab 103:3278-3288
Qiao, Yu; Xu, Meng; Tao, Junyan et al. (2018) Oncogenic potential of N-terminal deletion and S45Y mutant ?-catenin in promoting hepatocellular carcinoma development in mice. BMC Cancer 18:1093
Sarkar, Monika; Terrault, Norah; Duwaerts, Caroline C et al. (2018) The Association of Hispanic Ethnicity with Nonalcoholic Fatty Liver Disease in Polycystic Ovary Syndrome. Curr Opin Gynecol Obstet 1:24-33
Benet, Leslie Z; Bowman, Christine M; Liu, Shufang et al. (2018) The Extended Clearance Concept Following Oral and Intravenous Dosing: Theory and Critical Analyses. Pharm Res 35:242
Verstraete, Sofia G; Wojcicki, Janet M; Perito, Emily R et al. (2018) Bisphenol a increases risk for presumed non-alcoholic fatty liver disease in Hispanic adolescents in NHANES 2003-2010. Environ Health 17:12
Dave, S; Dodge, J L; Terrault, N A et al. (2018) Racial and Ethnic Differences in Graft Loss Among Female Liver Transplant Recipients. Transplant Proc 50:1413-1423
Maher, Jacquelyn J (2018) Macrophages Steal STING From the Infectious Disease Playbook to Promote Nonalcoholic Fatty Liver Disease. Gastroenterology 155:1687-1688
Cullaro, Giuseppe; Park, Meyeon; Lai, Jennifer C (2018) ""Normal"" Creatinine Levels Predict Persistent Kidney Injury and Waitlist Mortality in Outpatients With Cirrhosis. Hepatology 68:1953-1960
Lee, Brian P; Mehta, Neil; Platt, Laura et al. (2018) Outcomes of Early Liver Transplantation for Patients With Severe Alcoholic Hepatitis. Gastroenterology 155:422-430.e1
Campos-Varela, Isabel; Agudelo, Eliana Z; Sarkar, Monika et al. (2018) Use of a hepatitis C virus (HCV) RNA-positive donor in a treated HCV RNA-negative liver transplant recipient. Transpl Infect Dis 20:

Showing the most recent 10 out of 1119 publications